406-99-5

Basic information

• Product Name: 2-(2,2-DIFLUORO-PROPYLAMINO)-ETHANOL
• Synonyms: 2-(2,2-DIFLUORO-PROPYLAMINO)-ETHANOL
• CAS NO: 406-99-5
• Molecular Formula: C₅H₁₁F₂NO
• Molecular Weight: 139.14
• Product Categories: pharmacetical
• Mol File: 406-99-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 184.6 °C at 760 mmHg
• Flash Point: 65.4 °C
• Appearance: /
• Density: 1.084 g/cm³
• Vapor Pressure: 0.207mmHg at 25°C
• Refractive Index: 1.393
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(2,2-DIFLUORO-PROPYLAMINO)-ETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2,2-DIFLUORO-PROPYLAMINO)-ETHANOL(406-99-5)
• EPA Substance Registry System: 2-(2,2-DIFLUORO-PROPYLAMINO)-ETHANOL(406-99-5)

Safety Data

• Hazardous Substances Data: 406-99-5(Hazardous Substances Data)

Usage

General Description

2-(2,2-Difluoro-propylamino)-ethanol, also known as DFPAE, is a chemical compound with the molecular formula C5H10F2NO. It is a synthetic organic compound that contains a difluoropropylamino group attached to an ethanol backbone. DFPAE is commonly used as a building block and intermediate in the synthesis of pharmaceuticals and other organic compounds. It may also have applications in the field of medicinal chemistry and drug development. The compound's properties and potential uses make it an important target for researchers and chemists working in the area of chemical synthesis and drug discovery.

InChI:InChI=1/C5H11F2NO/c1-5(6,7)4-8-2-3-9/h8-9H,2-4H2,1H3

Upstream product

• 851728-91-1 2,2-difluoro-N-(2-hydroxyethyl)-propionamide 

Downstream Products

• 851729-03-8 acetic acid 3-[(2-chloroethyl)-(2,2-difluoropropyl)-carbamoyl]-1-(2-chlorophenyl)-5-(4-chlorophenyl)-1H-pyrazol-4-yl-ester 

Relevant articles and documents

Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)- 6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8-(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity

We report the design, synthesis, and structure-activity relationships of novel bicyclic lactam-based cannabinoid type 1 (CB1) receptor antagonists. Members of these series are potent, selective antagonists in in vitro/in vivo efficacy models of CB1 antagonism and exhibit robust oral activity in rodent models of food intake. These efforts led to the identification of 19d, which has been advanced to human clinical trials for weight management.

Bicyclic pyrazolyl and imidazolyl compounds and uses thereof

Compounds of Formula (I) are described herein. The compounds have been shown to act as cannabinoid receptor ligands and are therefore useful in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals.